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Incremental Value Compared With Clinical and Biochemical Markers
Sebastian J. Buss, MD,* Mostafa Emami, BSC,* Derliz Mereles, MD,* Grigorios Korosoglou, MD,*
Arnt V. Kristen, MD,* Andreas Voss, PHD,† Dieter Schellberg, PHD,‡§ Christian Zugck, MD,*
Christian Galuschky, MS, Evangelos Giannitsis, MD,* Ute Hegenbart, MD,¶ Anthony D. Ho, MD,¶
Hugo A. Katus, MD,* Stefan O. Schonland, MD,¶ Stefan E. Hardt, MD*
Heidelberg and Munich, Germany
Objectives The aim of the study was to determine whether longitudinal left ventricular (LV) function provides prognostic in-
formation in a large cohort of patients with systemic light-chain (AL) amyloidosis.
Background AL amyloidosis is associated with a high incidence of cardiovascular events. Reduced myocardial longitudinal
function is one of the hallmarks of myocardial involvement in this rare disease.
Methods Two hundred six consecutive patients with biopsy-proven AL amyloidosis were investigated in this prospective obser-
vational study. Echocardiographic imaging parameters, mean tissue Doppler-derived longitudinal strain (LS), and two-
dimensional global longitudinal strain (2D-GLS) of the LV, cardiac serological biomarkers, and comprehensive clinical
disease characteristics were assessed. The primary endpoint was all-cause mortality or heart transplantation.
Results After a median follow-up of 1207 days, LS and 2D-GLS were significant predictors of survival in AL amyloidosis.
The cutoff values discriminating survivors from nonsurvivors were 10.65% for LS and 11.78% for 2D-GLS. In
a multivariable echocardiographic Cox model, only diastolic dysfunction and 2D-GLS remained as independent
predictors of survival. In comprehensive clinical models, 2D-GLS (p  0.0001), diastolic dysfunction (p  0.01),
the pathologic free light chains (p  0.05), cardiac troponin-T (cTnT) (p  0.01), and the Karnofsky index (p 
0.001) remained as independent predictors. 2D-GLS delineated a superior prognostic value compared with that
derived from pathologic free light chains or cTnT in patients evaluated before firstline chemotherapy (n  113;
p  0.0001), and remained the only independent predictor besides the Karnofsky index in subjects with pre-
served LV ejection fraction (50%; n  127; p  0.01). LS and 2D-GLS both offered significant incremental in-
formation (p  0.001) for the assessment of outcome compared with clinical variables (age, Karnofsky index,
and New York Heart Association functional class) and serological biomarkers.
Conclusions In the largest serial investigation reported so far, reduced LV longitudinal function served as an independent pre-
dictor of survival in AL amyloidosis and offered incremental information beyond standard clinical and serological
parameters. (J Am Coll Cardiol 2012;60:1067–76) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.043Amyloidosis is a multisystem disease with extracellular
deposition of pathological insoluble beta-fibrillar proteins in
a number of different organs, including the heart (1,2).
Diagnosis and classification of amyloidosis is based on the
analysis of the deposited insoluble abnormal fibrils (3,4).
Involvement of the heart is seen in more than one-half of
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Longitudinal Function in AL Amyloidosis September 18, 2012:1067–76Cardiac biomarkers, such as cardiac
troponin-T (cTnT) and natriuretic
peptides, particularly N-terminal
pro–B-type natriuretic peptide
(NT-proBNP), play a central role
for the assessment of prognosis in
AL amyloidosis (8–10). Echocardi-
ography is one of the main diagnos-
tic tools used in patients with sus-
pected cardiomyopathies, including
cardiac involvement in AL amyloid-
osis (11,12). Non-Doppler–derived
echocardiographic parameters like
increased left ventricular (LV) wall
thickness and decreased fractional
shortening are independent predic-
tors of cardiac mortality in AL am-
yloidosis (7). Previous studies ele-
gantly demonstrated the usefulness
of tissue Doppler and strain imaging
(11,12) for diagnosis and staging of
cardiac dysfunction in patients with
AL amyloidosis (13–15). In addi-
tion, recent evidence found that tis-
sue Doppler imaging (TDI)-derived
myocardial systolic strain is associ-
ated with overall prognosis in AL
amyloidosis (16,17), but the prog-
nostic relevance of these parameters
in relation to hematologic parameters and cardiac biomarkers has
not been defined. Newer methods such as 2-dimensional strain
echocardiography (11,12), which have previously been shown to
have great clinical impact on other cardiovascular disorders
(18,19), have so far not been investigated regarding prognosis in
AL amyloidosis.
The purpose of this study was to clarify whether new
noninvasive imaging techniques, such as TDI, TDI-derived
strain imaging, and two-dimensional strain imaging provide
further prognostic information in addition to serum bio-
markers such as NT-proBNP and cTnT in a large cohort of
patients with AL amyloidosis over a long follow-up period.
Methods
Setting and participants. Three hundred thirteen consec-
utive patients with suspected or known systemic AL amy-
loidosis were assessed at the interdisciplinary Heidelberg
Amyloidosis Center and underwent evaluation of cardiac
involvement in AL amyloidosis from July 2005 to October
2008. Patients with hereditary, AA, or senile amyloidosis
(n  51) or localized amyloidosis (n  27) were excluded,
s were patients with significant valvular heart disease,
ersistent atrial fibrillation, or inadequate performance on
chocardiograms (n  29). Thus, the final study population
onsisted of 206 consecutive patients (112 males and 94
Abbreviations
and Acronyms
2D-GLS  two-dimensional
global longitudinal strain
AL  light-chain
cTnT  cardiac troponin-T
df  degree of freedom
E/e= ratio  ratio of peak
early diastolic mitral inflow
velocity (E) to peak early
diastolic mitral annular
velocity (e=)
EF  ejection fraction
IDI  integrated
discrimination improvement
LS  longitudinal strain
LV  left ventricular
MDRD  Modified Diet in
Renal Diseases
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
NYHA  New York Heart
Association
ROC  receiver-operating
characteristic
TDI  tissue Doppler
imagingemales) with proven systemic AL amyloidosis. Diagnosis of pL amyloidosis was based on presence of a monoclonal
ammopathy by serum electrophoresis, immunofixation on
erum and urine, and free light chain test, and confirmed by
ositive Congo red staining with birefringence under polar-
zed light of any biopsy (periumbilical fat aspiration, rectum,
r target organ), positive immunohistology for kappa or
ambda in the biopsy, and on the exclusion of hereditary
orms of amyloidosis. The institutional review board ap-
roved the study conforming to the Declaration of Helsinki
uidelines, and informed consent was obtained from all
ubjects. All clinical, echocardiographic, and laboratory test
esults were collected on the same day. A detailed descrip-
ion of the echocardiographic and laboratory methods is
iven in the Online Appendix.
chocardiography. We performed a standard echocardio-
raphic investigation with a commercially available ultra-
ound system (iE33, Philips Medical Systems), followed by
wo-dimensional color tissue Doppler recordings, for the
ffline assessment of tissue Doppler velocities and mean
ongitudinal strain (LS). The two-dimensional color tissue
oppler recordings with second harmonic imaging were
ollected during a brief breath hold, from the apical 4-, 2-,
nd 3-chamber views as previously described (Fig. 1A) (20).
or offline 2-dimensional strain imaging (radial, circumfer-
ntial, and longitudinal strain), the vendor independent
ffline 2D Cardiac Performance Analysis software
TomTec Imaging Systems, Munich, Germany) was
sed. For the assessment of global two-dimensional
ongitudinal strain (2D-GLS), we calculated the average
f the longitudinal systolic peak negative values obtained
rom the 6 LV segments in the apical 4-, 2-, and
-chamber views (Fig. 1B, Online Videos 1 and 2).
utcomes and follow-up. All-cause mortality or heart
ransplantation due to progressive disease (n  14) was the
rimary endpoint, because the classification of death is often
roblematic in AL amyloidosis. Follow-up was obtained by
eview of the patient’s hospital chart or telephone interview
ith the patient or relative.
tatistical analysis. Data were analyzed using SPSS Ver-
ion 19 (IBM Corporation) and MedCalc Version 11.5
MedCalc Software, Belgium). Data were expressed as
ean  SD. Group differences for continuous variables
ere tested using the unpaired t test, for ordinal variables
ith the Mann-Whitney test, and differences between
ominal variables were assessed using the Fisher exact test.
orrelation analyses were performed using Spearman’s co-
fficient. Kaplan-Meier curves were used to estimate the
istribution of survival as a function of the follow-up
uration. The association of clinical, echocardiographic, and
erological parameters with outcome was investigated by
ultivariable Cox proportional-hazards regression models.
n addition, integrated discrimination improvement analysis
as performed using the same hierarchical model (21).
eceiver-operating characteristics (ROCs) were used to
stimate the value of echocardiographic and serological
arameters to predict mortality. A subgroup analysis was
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September 18, 2012:1067–76 Longitudinal Function in AL Amyloidosisthen performed by fitting the final multivariable model
obtained in the overall analysis on the subgroup of patients
who received echocardiography before firstline chemother-
apy, with a preserved (50%) or reduced LV ejection
fraction (EF) (50%). Differences were considered statisti-
cally significant at p  0.05. The authors had full access to
he data and take responsibility for its integrity. All authors
ead and agreed to the paper as written.
esults
haracterization of study population. Two hundred six
atients were included in the final analysis. One patient was
ost at follow-up. The clinical characteristics as well as bio-
arkers are shown in Table 1. Standard two-dimensional
chocardiographic parameters as well as the parameters for
ongitudinal function and strain imaging are illustrated in
able 2 and Online Table 1. Eighty-seven patients were
reated with chemotherapy before study inclusion. Of those
atients who had an echocardiogram before chemotherapy
n  121), 37 (31%) received high-dose melphalan therapy,
2 (51%) received melphalan and dexamethasone, and 22
Figure 1 Measurement of Left Ventricular Longitudinal Functio
Representative images illustrating the methods for measurement of tissue Dopple
strain (2D-GLS) (B) in a patient with severe cardiac involvement in light-chain (AL)
markedly reduced. In these examples, LS is calculated from the mean value of the
arrow in A) or the mean peak negative strain (black arrow in B) of all 6 automati
all segments) in the apical 4-chamber view (B). Apical regions cannot be evaluate
tion, see Online Video 1 (standard ultrasound examination) and Online Video 2 (as18%) received other forms of therapy. sV longitudinal function. LV longitudinal function can
urrently be assessed without vigorous effort in a clinical
outine setting by the determination of LS and 2D-GLS.
oth yielded a very good correlation with NT-proBNP, but
lower correlation for cTnT. The Spearman correlation of
T-proBNP with LS was r0.79 (p 0.001), and with
D-GLS, it was r  0.72 (p  0.001). In contrast for
TnT, the values for LS were r  0.65 (p  0.001) and
 0.62 (p  0.001) for 2D-GLS.
urvival analysis. Of the 205 patients, 109 (53%) died or
eceived heart transplantation (n  14) during follow-up.
eceased patients had significantly lower values for clinical,
erological, and standard echocardiographic parameters as
ell as LV longitudinal function (Tables 1 and 2, Online
able 1). The median follow-up time after echocardiogra-
hy was 1,207 days (255 days for nonsurvivors and 1,796
ays for survivors). In the unadjusted univariate analysis
Table 3), clinical symptoms of congestive heart failure,
TnT, NT-proBNP, and parameters of myocardial mor-
hology and function, assessed with echocardiography, were
ll significantly associated with overall survival. The mea-
ved mean longitudinal strain (LS) (A) and two-dimensional global longitudinal
idosis, who died 1 month after echocardiography. With both methods, LS is
negative strain values derived from the “M-Line” regions of interest (white
egmented segments (colored lines; the black line represents the mean curve of
tissue Doppler due to the angle dependency of the method. For further illustra-
ent of GLS).n
r–deri
amylo
peak
cally s
d with
sessmures for LV longitudinal function, LS, and 2D-GLS were
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Longitudinal Function in AL Amyloidosis September 18, 2012:1067–76clearly associated with a reduced survival in patients with
AL amyloidosis (Fig. 2).
Proportional hazards models. Different echocardio-
graphic parameters that were previously attributed to be
prognostic in AL amyloidosis were further investigated for
their predictive value in all patients. First, in a stepwise Cox
regression analysis of relevant echocardiographic values
(including all strain variables) only 2D-GLS (p  0.001)
nd the ratio of peak early diastolic mitral inflow velocity
E) to peak early diastolic mitral annular velocity (e=) (E/e=
atio) (p  0.01) remained as independent predictors for
urvival. A representative multivariate model that covers
everal established echocardiographic parameters is shown
n Table 4. These results confirmed that global LV longi-
udinal function represented by 2D-GLS (hazard ratio
HR]: 0.82, p  0.0001) was an independent echocardio-
Clinical CharacteristicsTable 1 Clinical Characteristics
Parameter All Patients (n  206)
Age (yrs) 60 9
Male (%) 112 (54)
BMI (kg/m2) 25 4
Heart rate (beats/min) 80 15
Systolic blood pressure (mm Hg) 112 23
Diastolic blood pressure (mm Hg) 74 12
NYHA functional class 2 (1; 3)a
No. of amyloid organs involved 2.7 1
MDRD (ml/min/1.73 m2)* 60 32
Subjects with dialysis (%) 18 (9)
ECG low voltage present (%) 49 (24)
NT-proBNP (pg/ml) 2,579 (300; 6,871)†a
cTnT (g/l) 0.020 (0.005; 0.100)†
Mayo score‡ 2 (2; 3)
Free light chain difference§ (mg/l) 343 738
Karnofsky index (%) 77 9
Values are mean  SD or n (%). p Values are listed for survivors versus nonsurvivors. *Glomerular
uartile 3). ‡Mayo cardiac biomarker staging score (8). §Difference between pathologic and nonp
BMI  body mass index; cTnT  cardiac troponin-T; ECG  electrocardiography; NT-proBNP  N
Echocardiographic CharacteristicsTable 2 Echocardiographic Characteristics
Parameter All Patients (n  20
Left atrial volume index (ml/m2) 33.9 14
Septal wall thickness (mm) 15.2 3.6
LV mass index (g/m2) 138.8 45.5
Ejection fraction (%) 51.7 11.5
E/e= ratio 15.3 9.7
Pericardial effusion present (%) 92 (45)
Mitral annular plane systolic excursion (cm) 1.1 0.5
Tissue Doppler
Peak systolic mitral annular velocity (s) (cm/s) 7.0 2.6
Mean LS systolic (%) 10.4 5.7
2-dimensional
Mean 2D-radial peak positive strain (%) 27.8 9.9
Mean 2D-circumferential peak negative strain (%) 21.4 6.0
2D-GLS (%) 13.1 5.4Values are mean  SD or %. p Values are listed for survivors versus nonsurvivors.
E/e= ratio  ratio of peak early diastolic mitral inflow velocity (E) to peak early diastolic mitral annulargraphic predictor of survival along with a weak effect of
diastolic dysfunction represented by the E/e= ratio (HR:
1.02, p  0.035; Table 4).
For the final multivariate comprehensive clinical models
(n  198), which included well-recognized cardiac and
other risk factors for AL amyloidosis, we therefore chose
2D-GLS and the E/e= ratio as echocardiographic variables
(Table 5). In 5 patients, New York Heart Association
(NYHA) class was not available due to muscular disorders
because of polyneuropathy, and in 2 patients, serologic free
light chains values were missing. The model revealed the
Karnofsky index (HR: 0.94, p  0.0002), the free light
chain difference (HR: 1.0002, p 0.047), cTnT (HR: 1.97,
p 0.007), E/e= ratio (HR: 1.03, p 0.011), and 2D-GLS
HR: 0.85, p  0.0001) as the only significant independent
redictors of survival.
Nonsurvivors (n  109) Survivors (n  96) p Value
59 9 61 9 NS
64 (59) 48 (50) NS
24 4 25 4 NS
82 16 78 14 0.05
104 23 121 20 0.0001
70 13 79 9 0.0001
3 (2; 3)a 1 (0; 2)a 0.0001
2.8 1.1 2.6 1.1 NS
56 32 65 33 NS
10 (9) 8 (8) NS
33 (30) 16 (17) 0.01
5,214 (2,454; 12,112)† 430 (153; 2,147)† 0.0001
0.050 (0.020; 0.180)† 0.005 (0.005; 0.020)† 0.0001
3 (2; 3)† 2 (1; 2)† 0.0001
546 946 106 222 0.0001
73 8 81 7 0.0001
n rate estimated with the Modified Diet in Renal Diseases (MDRD) formula. †Median (quartile 1;
gic serologic free light chains. Karnofsky performance status scale.
al pro–B-type natriuretic peptide; NYHA  New York Heart Association.
Nonsurvivors (n  109) Survivors (n  96) p Value
37.0 13.5 30.5 13.9 0.001
16.7 3.7 13.4 2.7 0.001
156.4 48.0 119.2 33.2 0.0001
47.3 12.1 56.5 8.6 0.001
19.7 10.5 10.4 5.5 0.0001
64 (59) 27 (28) 0.0001
0.8 0.4 1.4 0.4 0.0001
5.8 2.3 8.4 2.2 0.0001
7.2 4.4 14.0 4.8 0.0001
26.2 9.6 29.7 9.8 0.01
20.0 5.7 23.1 6.0 0.001
9.8 4.4 16.7 3.8 0.0001filtratio6)velocity (e=); LS  longitudinal strain; 2D-GLS  two-dimensional global longitudinal strain.
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September 18, 2012:1067–76 Longitudinal Function in AL AmyloidosisTo further describe those patients who were evaluated by
echocardiography at the time of diagnosis before any first-
line chemotherapy (i.e., chemotherapy naive), we performed
the same analysis for this subgroup of patients (n  113).
Again, 2D-GLS (HR: 0.78, p  0.0001) was still an
independent predictor of survival in AL amyloidosis besides
the difference of free light chains (HR: 1.0008, p  0.005)
and cTnT (HR: 2.78, p  0.002) (Table 5).
In clinical routine, EF is one of the main parameters from
echocardiography used for risk stratification in various
cardiac diseases. We therefore investigated all patients with
an LVEF 50% (n  127). Interestingly, the Karnofsky
index (HR: 0.95, p  0.024) and 2D-GLS (HR: 0.86, p 
0.0018) were the only independent predictors of survival.
cTnT and the difference of free light chains were no longer
significant in this subgroup (Table 5). Similar results were
found in the subgroup of patients with a reduced EF 50%
(n 71). Here, the Karnofsky index (HR: 0.94, p 0.009),
cTnT (HR: 2.21, p 0.026), and 2D-GLS (HR: 0.86, p
0.012) remained as independent predictors of survival
(Online Table 2).
Including all subjects, the cutoff values discriminating
survivors from nonsurvivors with the highest sensitivity and
specificity were 10.65% for LS and 11.78% for 2D-
GLS, respectively. For NT-proBNP and cTnT, the values
were 3085 pg/ml and 0.01 g/l, respectively. The corre-
ponding Kaplan-Meier curves are presented in Figures 1A
o 1D, and a more detailed description of the ROC analysis
Univariate Analysis for Overall SurvivalTable 3 Univariate Analysis for Overall Survival
Variable HR 95% CI
p Value
(Unadjusted)
Age (yrs) 1.00 0.9902–1.0323 0.303
NYHA functional class (2)* 4.23 2.846–6.289 0.0001
Karnofsky index (%) 0.91 0.8876–0.9272 0.0001
MDRD† (ml/min/1.73 m2) 0.99 0.9884–1.0000 0.053
Free light chain difference‡ (mg/dl) 1.00 1.0009–1.0014 0.0001
cTnT (0.03 g/l)* 4.95 3.3308–7.3418 0.0001
Log NT-proBNP (pg/ml) 2.94 2.3473–3.6874 0.0001
ECG low voltage present* 1.78 1.1797–2.6713 0.01
Left atrial volume index (ml/m2) 1.03 1.0140–1.0367 0.0001
Ejection fraction (%) 0.94 0.9223–0.9503 0.0001
E/e= ratio 1.08 1.0596–1.0930 0.0001
Septal wall thickness (mm) 1.18 1.1287–1.2238 0.0001
LV mass index (g/m2) 1.01 1.0096–1.0169 0.0001
Pericardial effusion present* 2.95 2.0085–4.3281 0.0001
MAPSE (cm) 0.10 0.0617–0.1603 0.0001
LS (%) 0.80 0.7608–0.8356 0.0001
2D-RS (%) 0.97 0.9451–0.9852 0.001
2D-CS (%) 0.93 0.8985–0.9587 0.0001
2D-GLS (%) 0.77 0.7322–0.8054 0.0001
*Dichotomous variable. †Glomerular filtration rate estimated with the MDRD formula. ‡Difference
between pathologic and nonpathologic serologic free light chains.
LV  left ventricular; MAPSE  mitral annular plane systolic excursion; 2D-CS  mean
wo-dimensional circumferential peak negative strain; 2D-RSmean two-dimensional radial peak
ositive strain; other abbreviations as in Tables 1 and 2.s shown in the Online Appendix and Online Figure S1. fWe used different Cox models to further investigate the
ignificance of LS and 2D-GLS for the prediction of
utcome in AL amyloidosis. The addition of LS and
D-GLS to a model, including baseline clinical variables
nd biomarkers, led to a significant increase in the power of
he model. The model based on clinical variables (C:
onsisting of age, Karnofsky index, and NYHA class 2)
ith an overall chi-square (degree of freedom [df]  3) of
0.27, was improved by log NT-proBNP (chi-square 41.97,
f 1, p  0.001) and cTnT (chi-square 7.51, df  1, p 
.01), and further increased by LS (chi-square 16.81, df 
, p  0.001). Finally, 2D-GLS (chi-square 21.84, df  1,
 0.001) offered additional incremental information for
he assessment of outcome (Fig. 3A, Table 6). In 2 further
odels, we assessed the value of EF in addition to the
linical model and in comparison to echocardiographic
arameters (Figs. 3B and 3C, Table 6). These results were
erified by the integrated discrimination improvement anal-
sis. LV longitudinal strain (LS and 2D-GLS) yielded
igher integrated discrimination improvement values com-
ared with clinical variables, serological biomarkers, and
chocardiographic parameters (Table 6).
iscussion
e reported on the largest, so far, cohort of consecutive
atients with AL amyloidosis with systematic assessment of
V longitudinal function and its association with estab-
ished risk parameters regarding prognosis.
The main findings of this study were: 1) NT-proBNP
howed a strong correlation with parameters of longitudinal
unction (LS and 2D-GLS) in patients with AL amyloid-
sis; 2) the reduction of LS and 2D-GLS were both
ndependently associated with prognosis in AL amyloidosis
ompared with standard echocardiographic parameters; 3)
D-GLS and cTnT were independent predictors of survival
n AL amyloidosis; and 4) LS and 2D-GLS provided
ncremental value to the combination of NT-proBNP,
TnT, and clinical parameters.
The poor outcome in patients with AL amyloidosis is
ainly due to progressive cardiac dysfunction and limited
reatment options for them. The main goal of therapy is to
top the production of amyloidogenic light chains, because
his is associated with improvement of organ function (22),
nhanced quality of life (23), and survival (24,25). However,
n advanced cardiac disease, many patients cannot tolerate
he side effects of any chemotherapy. Furthermore, new
reatment strategies, including heart transplantation before
igh-dose chemotherapy and autologous stem cell support,
equire identification of patients at the highest risk of death
25). Thus, an early diagnosis of LV dysfunction with
efinition and classification of prognosis is crucial before
ny intervention.
The quantification of longitudinal function was consid-
red to be a better measure of contractile myocardial
unction than only the geometric change of the left ventricle
1072 Buss et al. JACC Vol. 60, No. 12, 2012
Longitudinal Function in AL Amyloidosis September 18, 2012:1067–76estimated by calculating EF (26). The motion along the long
axis of the heart is probably the most fundamental motion of
the ventricles—twisting and untwisting in combination with
longitudinal shortening (27). Longitudinal fibers are located in
the subendocardium and subepicardium within a helical band
as the underlying architecture of the heart (28). Given that
histology, as well as magnetic resonance tomographic observa-
tions, demonstrated that the subendocardial myocardium is
affected first by the disease (29) and, therefore, primarily
longitudinal fibers are involved, this might partially explain the
predominant prognostic implication of longitudinal function in
the patients with preserved EF.
In congestive heart failure due to ischemic and nonisch-
Figure 2 Overall Survival in Patients With AL Amyloidosis
Survival of patients with AL amyloidosis represented by Kaplan-Meier survival curves accor
(C) N-terminal pro–B-type natriuretic peptide (NT-proBNP), and (D) cardiac troponin-T (cTnTemic origin, the estimation of LV long-axis function bytwo-dimensional strain has emerged as an accurate predictor
of all-cause mortality (18,19). This was in line with our
results, because 2D-GLS still remained an independent
predictor also in these subjects, despite a reduced EF. Also
in aortic stenosis, LV longitudinal function was a measure of
severity of cardiac impairment and degree of fibrosis, when
the EF was still preserved (30–32). It was also demonstrated
that in subclinical patients with cardiovascular risk factors,
longitudinal function is impaired first (33). In contrast to a
more heterogenous disease such as myocardial infarction,
both longitudinal and circumferential deformations are
independent risk factors for outcome and remodeling (34).
With the development of modern echocardiographic
receiver-operator characteristic curvederived cutoff values for (A) LS, (B) 2D-GLS,
was determined as days from echocardiography. Abbreviations as in Figure 1.ding to
). Timesystems, the measurement of two-dimensional strain has
1073JACC Vol. 60, No. 12, 2012 Buss et al.
September 18, 2012:1067–76 Longitudinal Function in AL Amyloidosisbeen proven to be reliable, angle independent, and more
robust than TDI-derived strain, and can be calculated much
easier and faster from standard two-dimensional grayscale
images (35). Two-dimensional global longitudinal strain
Multivariable Proportional-Hazard ModelsTable 4 Multivariable Proportional-Hazard Models
Echocardiographic Model
(n  205) HR 95% CI p Value
Left atrial volume index (ml/m2) 0.9963 0.9807–1.0122 0.6471
Ejection fraction (%) 0.9926 0.9686–1.0171 0.5516
E/e= ratio 1.0241 1.0018–1.0469 0.0349
Septal wall thickness (mm) 1.0579 0.9586–1.1675 0.2653
Left ventricular mass index (g/m2) 0.9945 0.9865–1.0025 0.1766
Pericardial effusion present* 0.9713 0.6029–1.5646 0.9051
MAPSE (cm) 0.5994 0.2708–1.3270 0.2092
2D-GLS (%) 0.8151 0.7604–0.8737 0.0001
*Dichotomous variable.
Abbreviations as in Tables 2 and 3.
Comprehensive Clinical ModelsTable 5 Comprehensive Clinical Models
Variable HR 95% CI p Value
Comprehensive model (n  198)
Age (yrs) 0.9978 0.9739–1.0223 0.8601
NYHA functional class (2)* 1.2316 0.7001–2.1663 0.4721
Karnofsky index (%) 0.9442 0.9161–0.9730 0.0002
MDRD (ml/min/1.73 m2) 1.0011 0.9922–1.0101 0.8072
Free light chain difference (mg/l) 1.0002 1.0000–1.0003 0.0473
Log NT-proBNP (pg/ml) 1.0662 0.7006–1.6226 0.7658
cTnT (0.03 g/l)* 1.9666 1.2091–3.1987 0.0067
ECG low voltage present* 1.0302 0.6604–1.6072 0.8962
E/e= ratio 1.0290 1.0067–1.0518 0.0109
2D-GLS (%) 0.8511 0.7954–0.9106 0.0001
Comprehensive model, chemotherapy
naive patients (n  113)
Age (yrs) 1.0011 0.9738–1.0292 0.9382
NYHA functional class (2)* 1.1518 0.5512–2.4066 0.7084
Karnofsky index (%) 0.9682 0.9320–1.0058 0.0982
MDRD (ml/min/1.73 m2) 0.9983 0.9854–1.0114 0.8031
Free light chain difference (mg/l) 1.0008 1.0002–1.0014 0.0051
Log NT-proBNP (pg/ml) 0.6789 0.3426–1.3452 0.2694
cTnT (0.03 g/l)* 2.7820 1.4633–5.2893 0.0019
ECG low voltage present*a 0.8893 0.5259–1.5039 0.6632
E/e= ratio 1.0161 0.9894–1.0436 0.2424
2D-GLS (%) 0.7825 0.7135–0.8581 0.0001
Comprehensive model, EF 50%
(n  127)
Age (yrs) 1.0149 0.9798–1.0513 0.4117
NYHA functional class (2)* 1.0176 0.5336–1.9403 0.9581
Karnofsky index (%) 0.9483 0.9058–0.9927 0.0236
MDRD (ml/min/1.73 m2) 1.0013 0.9876–1.0152 0.8513
Free light chain difference (mg/l) 1.0005 0.9995–1.0016 0.3180
Log NT-proBNP (pg/ml) 1.0596 0.5542–2.0256 0.8618
cTnT (0.03 g/l)* 1.6893 0.7709–3.7017 0.1925
ECG low voltage present* 1.8030 0.9425–3.4493 0.0764
E/e= ratio 1.0265 0.9838–1.0710 0.2306
2D-GLS (%) 0.8590 0.7814–0.9444 0.0018
There are 5 missing NYHA muscular disorders due to polyneuropathy and 2 due to missing
serologic free light chains. *Dichotomous variable.
Abbreviations as in Tables 1, 2, and 3.Figure 3 Incremental Predictive Value of LS and 2D-GLS in
AL Amyloidosis
Three multivariate models were evaluated for the prediction of all-cause mortal-
ity in AL amyloidosis. In the first multivariate model, the clinical variables (age,
Karnofsky index [KI] and New York Heart Association (NYHA) class 2) were
entered together, followed by adding cTnT, log NT-proBNP, LS, and 2D-GLS. (A)
LS and 2D-GLS offered incremental prognostic information to the model (Table
6). (B) In the second model (Table 6), the clinical risk factors (age, KI, and
NYHA class 2) were entered together, followed by addition of cTnT, log NT-
proBNP, and the ejection fraction (EF). The EF offered an incremental value to
the clinical parameters and serological biomarkers. In the third model, only
echocardiographic parameters were included. (C) When starting with the EF,
followed by the E/e= ratio and, finally, with the two parameters of left ventricu-
lar longitudinal function, LS and 2D-GLS, both offered incremental prognostic
information (Table 6). Abbreviations as in Figure 1.
f
d
p
s
g
i
f
w
2
m
d
w
v
r
l
i
d
r
i
t
discrim
1074 Buss et al. JACC Vol. 60, No. 12, 2012
Longitudinal Function in AL Amyloidosis September 18, 2012:1067–76measures the whole ventricle, including the apex, and not
only the basal and midventricular segments, such as that in
TDI-derived strain. With the use of two-dimensional
Cardiac Performance Analysis, which is available for clinical
routine, it is now possible to measure 2D-GLS with the
same technique in studies recorded with different echocar-
diographic systems (36).
Systolic longitudinal strain and strain rate, as the current
methods used to measure myocardial longitudinal function,
seem to be more sensitive than myocardial systolic velocities
measured with TDI to detect myocardial amyloid deposi-
tion in patients with AL amyloidosis, especially in subclin-
ical disease (14,37). This notion is supported by other
imaging methods such as cardiovascular magnetic resonance
tomography, where the deposition of gadolinium, with a
typical subendocardial enhancement, matches the distribu-
tion of amyloid-associated myocardial fibrosis (38). This
deposition was independently associated with a poor prog-
nosis (38–40). As mentioned previously, the longitudinal
unction in patients with AL amyloidosis using TDI-
erived strain was reduced and also had an important
rognostic relevance. Unfortunately, none of the previous
tudies comprehensively included all current echocardio-
raphic and hematologic parameters, as well as biomarkers,
n their analyses. According to previous studies, we also
ound an incremental prognostic value for LS measured
ith TDI. With two-dimensional strain, represented by
D-GLS in this study, the subendocardial regions of the
yocardium and the apex can now be evaluated in more
etail, offering superior global strain information of the
hole left ventricle. This may explain why the incremental
alue of 2D-GLS is incremental to LS in the sequential Cox
egression models, as both represent a descriptor of LV
ongitudinal function. In addition, with this new method, it
s also possible to measure radial and circumferential two-
imensional deformation parameters. Both are significantly
educed in AL amyloidosis and associated with poor survival
n the univariate analysis; however, in our study population,
Comparison of Multivariate Cox Regression ModelsTable 6 Comparison of Multivariate Cox Regression Models
Model 1
Comparison of multivariate Cox-regression models (n  200)
C C  BNP
C  BNP C  BNP 
C  BNP  cTnT C  BNP 
C  BNP  cTnT LS C  BNP 
Clinical parameters and ejection fraction (n  200)
C C  BNP
C  BNP C  BNP 
C  BNP  cTnT C  BNP 
Echocardiographic parameters (n  205)
EF EF  E/e=
EF  E/e= EF  E/e= 
EF  E/e=  LS EF  E/e= 
C  Clinical model (age, NYHA class [dichotomous, cutoff 2], Karnofsky index); IDI  integratedhey did not remain as independent predictors. Thus,evaluation of longitudinal function with two-dimensional
deformation imaging might become the diagnostic method
of choice to detect early longitudinal functional impairment
and serve as a relevant echocardiographic “staging” param-
eter in patients with systemic AL amyloidosis.
In the present study, the largest serial investigation
reported so far, the reduced LV longitudinal function was
an independent predictor of survival in AL amyloidosis and
offered incremental information beyond standard clinical
and serological parameters. The data demonstrated that in
patients with a reduced EF (50%), but specifically in
patients with AL amyloidosis and a preserved EF (50%),
LV longitudinal function was one of the strongest prognos-
tic tools that could be used, irrespective of previous
therapies besides diastolic function, represented by the
E/e= ratio. This finding might be explained by the fact
that the estimation of EF alone underestimated the
severity of myocardial systolic dysfunction, especially in
the setting of LV hypertrophy (41). In summary, these
results underlined the great importance of both systolic
and diastolic functional impairment in AL amyloidosis in
concordance with independent predictors of survival,
such as biomarkers.
NT-proBNP, cardiac troponins, and serum free AL are
the currently recommended biomarkers for risk assessment
in AL amyloidosis. The elevation of NT-proBNP in AL
amyloidosis may reflect hormone production by cardiac
myocytes as a result of compression by amyloid deposits
(42). This suggests that elevated filling pressure is not the
only determinant of an elevated NT-proBNP level in AL
amyloidosis (43). Elevated levels of troponin and NT-
proBNP were reported to be very good predictors of survival
and are recommended for risk stratification in patients with
AL amyloidosis (9,10,44). In our study, NT-proBNP,
especially in contrast to cTnT, was highly correlated with
LV longitudinal function. One could argue that NT-
proBNP is a result of decreased longitudinal function and
enhanced LV wall stress, whereas cTnT mainly represents
2 Chi-square Difference p Value IDI
41.97 0.001 0.086
7.51 0.01 0.011
LS 16.81 0.001 0.027
LS  2D-GLS 21.84 0.001 0.042
41.97 0.001 0.086
7.51 0.01 0.011
EF 8.41 0.01 0.005
28.70 0.001 0.059
34.36 0.001 0.104
2D-GLS 28.51 0.001 0.057
ination improvement; other abbreviations as in Tables 1, 2, and 3.Model
cTnT
cTnT 
cTnT 
cTnT
cTnT 
LS
LS myocardial damage. Thus, in the final multivariate analysis,
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In accordance with previous studies, we confirmed that
serum free ALs provided important prognostic information
together with cTnT and 2D-GLS, especially in patients
who were referred before any specific therapy for AL
amyloidosis (45).
It is known that the level of cardiac biomarkers can be
reduced if the applied chemotherapy has successfully erad-
icated the plasma clone in the bone marrow in AL amy-
loidosis (46). Furthermore, recent reports described the
possibility of halting organ progression by using small
molecules of tafamidis and diflunisal in TTR amyloidosis
(47), eprodisate in AA amyloidosis (48), or reducing amy-
loid deposits by the SAP chelator CPHPC (49), as well as
using the green tea polyphenol, epigallocatechin-3-gallate
(50,51) in several forms of amyloidoses. Prospective clinical
studies are needed to confirm these precursors or amyloid-
directed effects and show whether the echocardiographic
parameters analyzed in this study will also improve after
successful therapy.
Conclusions
LV longitudinal function is significantly associated with car-
diac biomarkers and increased mortality in AL amyloidosis.
New echocardiographic parameters identified patients with the
highest risk and served as independent predictors of survival.
Quantification of LV longitudinal function by LS and 2D-
GLS provided incremental prognostic value regarding cardio-
vascular outcome in AL amyloidosis and seemed to be superior
to standard echocardiography and cardiac biomarkers. Thus, it
might become the method of choice for the description of LV
function in systemic AL amyloidosis. We therefore propose
measurement of LV longitudinal function as a standard pro-
cedure for staging of patients with AL amyloidosis.
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